AMRX - Amneal Pharma reaffirms 2022 guidance

• Generic and specialty drugmaker Amneal Pharmaceuticals ( NYSE: AMRX ) reiterated its previously issued financial guidance for the year ending December 31, 2022, on Tuesday as part of its presentation at the ongoing JPMorgan Healthcare Conference.
• The detailed outlook indicates $2.15B – $2.25B in net revenue and $0.65 – $0.70 of adjusted diluted earnings per share for the year, in line with the $2.18B and $0.66 in the consensus, respectively. In comparison, Amneal ( AMRX ) reported ~$2.1B of net revenue and $0.85 of adj. diluted EPS for 2021.
• The company also expects its adjusted EBITDA, operating cash flow, and capital expenditure to reach $500M – $520M, $200M – $225M, and $65M – $75M in 2022, respectively.
• In October, noting the company’s ongoing transformation, Seeking Alpha contributor Bret Jensen argued that Amneal ( AMRX ) “appears worthy of a small investment at current trading levels,”

For further details see: